PCI Synthesis is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, Mass. and is the largest small molecule drug substance manufacturer in New England. A wholly-owned subsidiary of Novacap, PCI Synthesis is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a CDMO, PCI Synthesis provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. PCI Synthesis offers cGMP solutions to develop a final API, including process research, process development, analytical development, process validation, regulatory support & FDA filing. PCI Synthesis operates two FDA inspected sites in the Boston area. Please visit www.pcisynthesis.com.
This 40 year old company has an outstanding reputation for customer service, quality research, quality control and testing in bacteriology, mycology, virology, chemistry and in vitrotoxicology. Gibraltar Laboratories Inc. serves the pharmaceutical, medical device, orthopedic, tissue bank,... Read More
Swiss-American Contract Development and Manufacturing specializes in topical skin and wound care products. Our product development and manufacturing processes are complemented by a flexible and innovative R&D capability. For more than 25 years, leading healthcare brands have relied on our... Read More
CrownBio’s fast-paced R&D programs are yielding novel, yet well-validated models at the cutting-edge of disease research. Our unique MuPrime™ models, as well as Humanized GEMMs (HuGEMM™) and Patient-Derived Xenograft (PDX) models are leading the way in advanced immuno-oncology, whilst the...
PCI Synthesis offers a wide range of chemical products including: Aromatics, Imidazoles/Imidazolines, Indoles, Oxazoles, Phosphonic acids, photo imaging, Purines, Pyridines, Pyrimidines and Tetralones. They are immediately available for shipment. Read more